U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07163507) titled 'Immune Response Under Immunotherapy in Lung Cancer: Study of Sputum Samples' on Sept. 01.
Brief Summary: Lung cancer is the leading cause of cancer-related death worldwide, with nearly 2.48 million cases and 1.8 million deaths in 2022. Despite therapeutic progress, late diagnosis and high mortality make it a major public health issue. Immune checkpoint inhibitors (ICI) such as nivolumab, pembrolizumab, and atezolizumab have improved outcomes for some patients, but only a small proportion benefit, and side effects can be severe. Research is focusing on combining ICIs with chemotherapy, radiotherapy, or other immunotherapies, but rel...